Jun 18, 2020
Aridis Pharmaceuticals to Discuss APEX(TM) in Virtual Fireside Chat Hosted by Cantor Fitzgerald on June 25th
Jun 15, 2020
Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer
May 28, 2020
Microbion Awarded up to $17.1 Million from CARB-X and the Cystic Fibrosis Foundation to Develop Inhaled Antimicrobial for Chronic Respiratory Infections in CF
May 27, 2020
Microbion Corporation Announces Orphan Drug Designation Granted for Pravibismane Suspension for Inhalation by US FDA
Apr 29, 2020
Aridis Pharmaceuticals to Participate in Maxim Group's Infectious Disease Virtual Conference
Mar 25, 2020
Forge Enters Into Collaboration With Roche To Develop Novel Antibiotic To Treat Lung Infections
Mar 06, 2020
Aridis Pharmaceuticals to Postpone Investor Day Due to Coronavirus Concerns
Mar 05, 2020
Aridis Pharmaceuticals to Present at the 32nd Annual ROTH Conference
Mar 04, 2020
Aridis Pharmaceuticals Provides Update on Investor Day Featuring Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia
Feb 18, 2020
Aridis Pharmaceuticals to Host Investor Day Showcasing APEX(TM) Technology Platform and Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia
Jan 28, 2020
Aridis Pharmaceuticals Presents APEX(TM) Antibody Discovery and Production Platform Technology at the 19th Annual CHI PepTalk Conference
Jan 02, 2020
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
Oct 22, 2019
Qpex Biopharma and Brii Biosciences Enter Into a Strategic Collaboration to Develop and Commercialize Antibiotics for Drug-Resistant Infections in China
Oct 11, 2019
Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer
Sep 27, 2019
Aridis Pharmaceuticals to Present AR-105 and AR-501 (Gallium Citrate) Data at IDWeek(TM) 2019
Sep 27, 2019
Aridis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
Sep 26, 2019
Acute Bacterial Skin and Skin Structure Infections Pipeline Insight Report 2019
Sep 25, 2019
Qpex Biopharma to Present its Anti-infective Portfolio at IDWeek 2019
Sep 08, 2019
Aridis Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference on September 10, 2019
Sep 03, 2019
Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa